Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$0.85 - $1.87 $6.77 Million - $14.9 Million
7,965,865 New
7,965,865 $8.2 Billion
Q2 2023

Aug 11, 2023

BUY
$0.73 - $2.37 $1.1 Million - $3.56 Million
1,500,000 New
1,500,000 $2.9 Million
Q4 2021

Feb 14, 2022

SELL
$2.2 - $4.46 $3.79 Million - $7.69 Million
-1,724,201 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$3.85 - $6.44 $4.93 Million - $8.25 Million
1,280,694 Added 288.77%
1,724,201 $6.76 Million
Q2 2021

Aug 16, 2021

BUY
$5.85 - $8.33 $1.16 Million - $1.66 Million
198,992 Added 81.38%
443,507 $2.84 Million
Q1 2021

May 14, 2021

SELL
$7.8 - $12.43 $1.05 Million - $1.68 Million
-134,955 Reduced 35.56%
244,515 $1.98 Million
Q4 2020

Feb 12, 2021

BUY
$4.07 - $11.0 $1.54 Million - $4.17 Million
379,470 New
379,470 $3.18 Million

Others Institutions Holding GMDA

# of Institutions
1
Shares Held
2.2K
Call Options Held
0
Put Options Held
0

About Gamida Cell Ltd.


  • Ticker GMDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,319,600
  • Market Cap $2.29M
  • Description
  • Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...
More about GMDA
Track This Portfolio

Track Stonepine Capital Management, LLC Portfolio

Follow Stonepine Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stonepine Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stonepine Capital Management, LLC with notifications on news.